Ethanolamine oleate in resistant idiopathic achalasia: a novel therapy
OBJECTIVESIdiopathic achalasia (IA) is a chronic disease without definite therapy. Ethanolamine oleate (EO) has multiple biological effects, including inflammatory activities. We investigated the efficacy of EO injection in selected patients with IA. METHODSOne hundred and thirty-six patients with I...
Gespeichert in:
| Veröffentlicht in: | European journal of gastroenterology & hepatology 2011-11, Vol.23 (12), p.1111-1115 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1115 |
|---|---|
| container_issue | 12 |
| container_start_page | 1111 |
| container_title | European journal of gastroenterology & hepatology |
| container_volume | 23 |
| creator | Niknam, Ramin Mikaeli, Javad Mehrabi, Narges Mahmoudi, Laleh Elahi, Elham Shirani, Shapoor Malekzadeh, Reza |
| description | OBJECTIVESIdiopathic achalasia (IA) is a chronic disease without definite therapy. Ethanolamine oleate (EO) has multiple biological effects, including inflammatory activities. We investigated the efficacy of EO injection in selected patients with IA.
METHODSOne hundred and thirty-six patients with IA were evaluated prospectively. We evaluated the efficacy of EO injection in 13 patients with IA that are resistant to or a poor candidate of pneumatic balloon dilation and/or cardiomyotomy at the Digestive Disease Research Center, Shariati Hospital, Tehran, as the major referral center for achalasia in Iran in an interventional study. Diluted EO was injected in a divided dose into each of four quadrants of lower esophageal sphincter, using a standard sclerotherapy needle. Injection was repeated at 2 and 4 weeks after first injection. The patients were evaluated with achalasia symptom score (ASS) and timed barium esophagogram (TBE) before and after injections. Good response was defined as a decrease in ASS of at least 50% of baseline and decrease in height and volume of barium of at least 50% of baseline in TBE, at 1.5 months after the last injection. Side-effects were recorded.
RESULTSAll patients (13 cases) had good ASS (decreased, ≥50%) and good TBE (decreased in height and volume of barium, ≥50%) response rate. The mean ASS decreased from 11.38 (±1.5) to 3.23 (±1.96) at 1.5 months after the last injection (P=0.001). The mean volume of barium in TBE decreased from 81.38 ml (±51.11) to 40.69 ml (±61.22) at 1.5 months after the last injection (P=0.016). The mean duration of follow-up was 17.83 (±1.12) months. Symptoms of six patients relapsed; all of them were treated effectively with reinjection.
CONCLUSIONThis study indicates that EO is well tolerated and potentially effective in patients with IA that might be explained by the local inflammatory properties of EO. As presented data are too preliminary to support the routine use of EO in the treatment of all patients with IA; its use in selected cases can be considered. |
| doi_str_mv | 10.1097/MEG.0b013e328349647e |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_903148627</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>903148627</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3303-65e3544c95ff621428b359d573e8ff6ea1d95350ed931598d64b827e5e40fa8e3</originalsourceid><addsrcrecordid>eNpdkEFr3DAQhUVpaLZp_0EJvpSenGg0kmXlFsImLST00kJvYtYeY7VaeyNpG_Lv65JtAzkMwwzfmzc8IT6APAPp7Pnd-uZMbiQgo2pRu0ZbfiVWoC3Wpmnta7GSzui6cfDjWLzN-aeUYBHsG3GswFlA26zE9bqMNM2RtmHiao5MhaswVYlzyIWmUoU-zDsqY-gq6kaKlANdVFRN82-OVRk50e7xnTgaKGZ-f-gn4vv1-tvV5_r2682Xq8vbukOUWDeG0WjdOTMMjQKt2g0a1xuL3C4bJuidQSO5dwjGtX2jN62ybFjLgVrGE_Hp6e4uzfd7zsVvQ-44Rpp43mfvJIJuG2UXUj-RXZpzTjz4XQpbSo8epP8boF8C9C8DXGSnB4P9Zsv9f9G_xBbg4wGg3FEcEk1dyM-ctg6UUc_-D3MsnPKvuH_g5EemWEYvpdTLk7ZWEgDUMtZLScQ_pK6IYg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>903148627</pqid></control><display><type>article</type><title>Ethanolamine oleate in resistant idiopathic achalasia: a novel therapy</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Niknam, Ramin ; Mikaeli, Javad ; Mehrabi, Narges ; Mahmoudi, Laleh ; Elahi, Elham ; Shirani, Shapoor ; Malekzadeh, Reza</creator><creatorcontrib>Niknam, Ramin ; Mikaeli, Javad ; Mehrabi, Narges ; Mahmoudi, Laleh ; Elahi, Elham ; Shirani, Shapoor ; Malekzadeh, Reza</creatorcontrib><description>OBJECTIVESIdiopathic achalasia (IA) is a chronic disease without definite therapy. Ethanolamine oleate (EO) has multiple biological effects, including inflammatory activities. We investigated the efficacy of EO injection in selected patients with IA.
METHODSOne hundred and thirty-six patients with IA were evaluated prospectively. We evaluated the efficacy of EO injection in 13 patients with IA that are resistant to or a poor candidate of pneumatic balloon dilation and/or cardiomyotomy at the Digestive Disease Research Center, Shariati Hospital, Tehran, as the major referral center for achalasia in Iran in an interventional study. Diluted EO was injected in a divided dose into each of four quadrants of lower esophageal sphincter, using a standard sclerotherapy needle. Injection was repeated at 2 and 4 weeks after first injection. The patients were evaluated with achalasia symptom score (ASS) and timed barium esophagogram (TBE) before and after injections. Good response was defined as a decrease in ASS of at least 50% of baseline and decrease in height and volume of barium of at least 50% of baseline in TBE, at 1.5 months after the last injection. Side-effects were recorded.
RESULTSAll patients (13 cases) had good ASS (decreased, ≥50%) and good TBE (decreased in height and volume of barium, ≥50%) response rate. The mean ASS decreased from 11.38 (±1.5) to 3.23 (±1.96) at 1.5 months after the last injection (P=0.001). The mean volume of barium in TBE decreased from 81.38 ml (±51.11) to 40.69 ml (±61.22) at 1.5 months after the last injection (P=0.016). The mean duration of follow-up was 17.83 (±1.12) months. Symptoms of six patients relapsed; all of them were treated effectively with reinjection.
CONCLUSIONThis study indicates that EO is well tolerated and potentially effective in patients with IA that might be explained by the local inflammatory properties of EO. As presented data are too preliminary to support the routine use of EO in the treatment of all patients with IA; its use in selected cases can be considered.</description><identifier>ISSN: 0954-691X</identifier><identifier>EISSN: 1473-5687</identifier><identifier>DOI: 10.1097/MEG.0b013e328349647e</identifier><identifier>PMID: 21971376</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins, Inc</publisher><subject>Adult ; Biological and medical sciences ; Deglutition Disorders - etiology ; Esophageal Achalasia - complications ; Esophageal Achalasia - diagnosis ; Esophageal Achalasia - therapy ; Esophagus ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Injections, Intralesional ; Male ; Malformations ; Medical sciences ; Middle Aged ; Oleic Acids - administration & dosage ; Oleic Acids - therapeutic use ; Prospective Studies ; Sclerosing Solutions - administration & dosage ; Sclerosing Solutions - therapeutic use ; Sclerotherapy - methods ; Severity of Illness Index ; Treatment Outcome</subject><ispartof>European journal of gastroenterology & hepatology, 2011-11, Vol.23 (12), p.1111-1115</ispartof><rights>2011 Lippincott Williams & Wilkins, Inc.</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3303-65e3544c95ff621428b359d573e8ff6ea1d95350ed931598d64b827e5e40fa8e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24791252$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21971376$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Niknam, Ramin</creatorcontrib><creatorcontrib>Mikaeli, Javad</creatorcontrib><creatorcontrib>Mehrabi, Narges</creatorcontrib><creatorcontrib>Mahmoudi, Laleh</creatorcontrib><creatorcontrib>Elahi, Elham</creatorcontrib><creatorcontrib>Shirani, Shapoor</creatorcontrib><creatorcontrib>Malekzadeh, Reza</creatorcontrib><title>Ethanolamine oleate in resistant idiopathic achalasia: a novel therapy</title><title>European journal of gastroenterology & hepatology</title><addtitle>Eur J Gastroenterol Hepatol</addtitle><description>OBJECTIVESIdiopathic achalasia (IA) is a chronic disease without definite therapy. Ethanolamine oleate (EO) has multiple biological effects, including inflammatory activities. We investigated the efficacy of EO injection in selected patients with IA.
METHODSOne hundred and thirty-six patients with IA were evaluated prospectively. We evaluated the efficacy of EO injection in 13 patients with IA that are resistant to or a poor candidate of pneumatic balloon dilation and/or cardiomyotomy at the Digestive Disease Research Center, Shariati Hospital, Tehran, as the major referral center for achalasia in Iran in an interventional study. Diluted EO was injected in a divided dose into each of four quadrants of lower esophageal sphincter, using a standard sclerotherapy needle. Injection was repeated at 2 and 4 weeks after first injection. The patients were evaluated with achalasia symptom score (ASS) and timed barium esophagogram (TBE) before and after injections. Good response was defined as a decrease in ASS of at least 50% of baseline and decrease in height and volume of barium of at least 50% of baseline in TBE, at 1.5 months after the last injection. Side-effects were recorded.
RESULTSAll patients (13 cases) had good ASS (decreased, ≥50%) and good TBE (decreased in height and volume of barium, ≥50%) response rate. The mean ASS decreased from 11.38 (±1.5) to 3.23 (±1.96) at 1.5 months after the last injection (P=0.001). The mean volume of barium in TBE decreased from 81.38 ml (±51.11) to 40.69 ml (±61.22) at 1.5 months after the last injection (P=0.016). The mean duration of follow-up was 17.83 (±1.12) months. Symptoms of six patients relapsed; all of them were treated effectively with reinjection.
CONCLUSIONThis study indicates that EO is well tolerated and potentially effective in patients with IA that might be explained by the local inflammatory properties of EO. As presented data are too preliminary to support the routine use of EO in the treatment of all patients with IA; its use in selected cases can be considered.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Deglutition Disorders - etiology</subject><subject>Esophageal Achalasia - complications</subject><subject>Esophageal Achalasia - diagnosis</subject><subject>Esophageal Achalasia - therapy</subject><subject>Esophagus</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Humans</subject><subject>Injections, Intralesional</subject><subject>Male</subject><subject>Malformations</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Oleic Acids - administration & dosage</subject><subject>Oleic Acids - therapeutic use</subject><subject>Prospective Studies</subject><subject>Sclerosing Solutions - administration & dosage</subject><subject>Sclerosing Solutions - therapeutic use</subject><subject>Sclerotherapy - methods</subject><subject>Severity of Illness Index</subject><subject>Treatment Outcome</subject><issn>0954-691X</issn><issn>1473-5687</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkEFr3DAQhUVpaLZp_0EJvpSenGg0kmXlFsImLST00kJvYtYeY7VaeyNpG_Lv65JtAzkMwwzfmzc8IT6APAPp7Pnd-uZMbiQgo2pRu0ZbfiVWoC3Wpmnta7GSzui6cfDjWLzN-aeUYBHsG3GswFlA26zE9bqMNM2RtmHiao5MhaswVYlzyIWmUoU-zDsqY-gq6kaKlANdVFRN82-OVRk50e7xnTgaKGZ-f-gn4vv1-tvV5_r2682Xq8vbukOUWDeG0WjdOTMMjQKt2g0a1xuL3C4bJuidQSO5dwjGtX2jN62ybFjLgVrGE_Hp6e4uzfd7zsVvQ-44Rpp43mfvJIJuG2UXUj-RXZpzTjz4XQpbSo8epP8boF8C9C8DXGSnB4P9Zsv9f9G_xBbg4wGg3FEcEk1dyM-ctg6UUc_-D3MsnPKvuH_g5EemWEYvpdTLk7ZWEgDUMtZLScQ_pK6IYg</recordid><startdate>20111101</startdate><enddate>20111101</enddate><creator>Niknam, Ramin</creator><creator>Mikaeli, Javad</creator><creator>Mehrabi, Narges</creator><creator>Mahmoudi, Laleh</creator><creator>Elahi, Elham</creator><creator>Shirani, Shapoor</creator><creator>Malekzadeh, Reza</creator><general>Lippincott Williams & Wilkins, Inc</general><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20111101</creationdate><title>Ethanolamine oleate in resistant idiopathic achalasia: a novel therapy</title><author>Niknam, Ramin ; Mikaeli, Javad ; Mehrabi, Narges ; Mahmoudi, Laleh ; Elahi, Elham ; Shirani, Shapoor ; Malekzadeh, Reza</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3303-65e3544c95ff621428b359d573e8ff6ea1d95350ed931598d64b827e5e40fa8e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Deglutition Disorders - etiology</topic><topic>Esophageal Achalasia - complications</topic><topic>Esophageal Achalasia - diagnosis</topic><topic>Esophageal Achalasia - therapy</topic><topic>Esophagus</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Humans</topic><topic>Injections, Intralesional</topic><topic>Male</topic><topic>Malformations</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Oleic Acids - administration & dosage</topic><topic>Oleic Acids - therapeutic use</topic><topic>Prospective Studies</topic><topic>Sclerosing Solutions - administration & dosage</topic><topic>Sclerosing Solutions - therapeutic use</topic><topic>Sclerotherapy - methods</topic><topic>Severity of Illness Index</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Niknam, Ramin</creatorcontrib><creatorcontrib>Mikaeli, Javad</creatorcontrib><creatorcontrib>Mehrabi, Narges</creatorcontrib><creatorcontrib>Mahmoudi, Laleh</creatorcontrib><creatorcontrib>Elahi, Elham</creatorcontrib><creatorcontrib>Shirani, Shapoor</creatorcontrib><creatorcontrib>Malekzadeh, Reza</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of gastroenterology & hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Niknam, Ramin</au><au>Mikaeli, Javad</au><au>Mehrabi, Narges</au><au>Mahmoudi, Laleh</au><au>Elahi, Elham</au><au>Shirani, Shapoor</au><au>Malekzadeh, Reza</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ethanolamine oleate in resistant idiopathic achalasia: a novel therapy</atitle><jtitle>European journal of gastroenterology & hepatology</jtitle><addtitle>Eur J Gastroenterol Hepatol</addtitle><date>2011-11-01</date><risdate>2011</risdate><volume>23</volume><issue>12</issue><spage>1111</spage><epage>1115</epage><pages>1111-1115</pages><issn>0954-691X</issn><eissn>1473-5687</eissn><abstract>OBJECTIVESIdiopathic achalasia (IA) is a chronic disease without definite therapy. Ethanolamine oleate (EO) has multiple biological effects, including inflammatory activities. We investigated the efficacy of EO injection in selected patients with IA.
METHODSOne hundred and thirty-six patients with IA were evaluated prospectively. We evaluated the efficacy of EO injection in 13 patients with IA that are resistant to or a poor candidate of pneumatic balloon dilation and/or cardiomyotomy at the Digestive Disease Research Center, Shariati Hospital, Tehran, as the major referral center for achalasia in Iran in an interventional study. Diluted EO was injected in a divided dose into each of four quadrants of lower esophageal sphincter, using a standard sclerotherapy needle. Injection was repeated at 2 and 4 weeks after first injection. The patients were evaluated with achalasia symptom score (ASS) and timed barium esophagogram (TBE) before and after injections. Good response was defined as a decrease in ASS of at least 50% of baseline and decrease in height and volume of barium of at least 50% of baseline in TBE, at 1.5 months after the last injection. Side-effects were recorded.
RESULTSAll patients (13 cases) had good ASS (decreased, ≥50%) and good TBE (decreased in height and volume of barium, ≥50%) response rate. The mean ASS decreased from 11.38 (±1.5) to 3.23 (±1.96) at 1.5 months after the last injection (P=0.001). The mean volume of barium in TBE decreased from 81.38 ml (±51.11) to 40.69 ml (±61.22) at 1.5 months after the last injection (P=0.016). The mean duration of follow-up was 17.83 (±1.12) months. Symptoms of six patients relapsed; all of them were treated effectively with reinjection.
CONCLUSIONThis study indicates that EO is well tolerated and potentially effective in patients with IA that might be explained by the local inflammatory properties of EO. As presented data are too preliminary to support the routine use of EO in the treatment of all patients with IA; its use in selected cases can be considered.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins, Inc</pub><pmid>21971376</pmid><doi>10.1097/MEG.0b013e328349647e</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0954-691X |
| ispartof | European journal of gastroenterology & hepatology, 2011-11, Vol.23 (12), p.1111-1115 |
| issn | 0954-691X 1473-5687 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_903148627 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adult Biological and medical sciences Deglutition Disorders - etiology Esophageal Achalasia - complications Esophageal Achalasia - diagnosis Esophageal Achalasia - therapy Esophagus Female Gastroenterology. Liver. Pancreas. Abdomen Humans Injections, Intralesional Male Malformations Medical sciences Middle Aged Oleic Acids - administration & dosage Oleic Acids - therapeutic use Prospective Studies Sclerosing Solutions - administration & dosage Sclerosing Solutions - therapeutic use Sclerotherapy - methods Severity of Illness Index Treatment Outcome |
| title | Ethanolamine oleate in resistant idiopathic achalasia: a novel therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T15%3A30%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ethanolamine%20oleate%20in%20resistant%20idiopathic%20achalasia:%20a%20novel%20therapy&rft.jtitle=European%20journal%20of%20gastroenterology%20&%20hepatology&rft.au=Niknam,%20Ramin&rft.date=2011-11-01&rft.volume=23&rft.issue=12&rft.spage=1111&rft.epage=1115&rft.pages=1111-1115&rft.issn=0954-691X&rft.eissn=1473-5687&rft_id=info:doi/10.1097/MEG.0b013e328349647e&rft_dat=%3Cproquest_cross%3E903148627%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=903148627&rft_id=info:pmid/21971376&rfr_iscdi=true |